|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/14/12 AIM ImmunoTech Inc. 10-K 12/31/11 48:5.4M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.21M
2: EX-10.21 Material Contract HTML 32K
3: EX-10.22 Material Contract HTML 29K
4: EX-21 Subsidiaries List HTML 14K
5: EX-23.1 Consent of Experts or Counsel HTML 16K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 15K
31: R1 Document and Entity Information HTML 44K
23: R2 Consolidated Balance Sheets HTML 148K
28: R3 Consolidated Balance Sheets (Parenthetical) HTML 41K
33: R4 Consolidated Statements of Comprehensive Loss HTML 74K
44: R5 Consolidated Statements of Changes in HTML 76K
Stockholders' Equity and Comprehensive Loss
24: R6 Consolidated Statements of Changes in HTML 18K
Stockholders' Equity and Comprehensive Loss
(Parenthetical)
27: R7 Consolidated Statements of Cash Flows HTML 140K
22: R8 Business HTML 23K
17: R9 Summary of Significant Accounting Policies HTML 41K
45: R10 Inventories and Other Assets HTML 26K
35: R11 Options HTML 93K
34: R12 Marketable Securities - Unrestricted HTML 56K
39: R13 Marketable Securities - Restricted HTML 34K
40: R14 Patents, Trademark Rights and Other Intangibles HTML 19K
38: R15 Accrued Expenses HTML 22K
41: R16 Stockholders' Equity HTML 275K
29: R17 Segment and Related Information HTML 24K
32: R18 Research, Consulting and Supply Agreements HTML 34K
37: R19 401(k) Plan HTML 26K
48: R20 Royalities, License and Employment Agreements HTML 24K
42: R21 Leases HTML 22K
25: R22 Income Taxes And Subsequent Event HTML 31K
36: R23 Contingencies HTML 36K
26: R24 Certain Relationships and Related Transactions HTML 29K
16: R25 Concentrations of Credit Risk HTML 21K
43: R26 Fair Value HTML 67K
46: R27 Capital Leases HTML 24K
20: R28 Margin Account Loan HTML 19K
19: R29 Subsequent Events HTML 17K
21: R30 Quarterly Results of Operation HTML 47K
47: XML IDEA XML File -- Filing Summary XML 60K
18: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 698K
10: EX-101.INS XBRL Instance -- heb-20111231 XML 874K
12: EX-101.CAL XBRL Calculations -- heb-20111231_cal XML 97K
13: EX-101.DEF XBRL Definitions -- heb-20111231_def XML 44K
14: EX-101.LAB XBRL Labels -- heb-20111231_lab XML 429K
15: EX-101.PRE XBRL Presentations -- heb-20111231_pre XML 262K
11: EX-101.SCH XBRL Schema -- heb-20111231 XSD 65K
30: ZIP XBRL Zipped Folder -- 0001144204-12-014793-xbrl Zip 79K
Exhibit 10.22
Fourth Amendment to Supply Agreement
This Amendment (this “Amendment”) effective as of March 11, 2011 (the “Amendment Date”) to the Supply Agreement (the “Agreement”), entered into on December 8, 2005, and previously amended on February 28, 2006, September 5, 2006, and February 26, 2010, between Hemispherx Biopharma, Inc. (hereinafter “Hemispherx”), and Jubilant HollisterStier LLC (formerly known as Hollister-Stier Laboratories LLC (hereinafter “Hollister-Stier”). Hemispherx and Hollister-Stier are each a “Party” and collectively, the “Parties”.
Whereas, the Parties wish to amend the Agreement regarding, among other things, postponement and cancellation of purchase orders; and
Whereas, all terms used, but not defined, herein shall have the respective meanings set forth in the Agreement.
Now, Therefore, in consideration of the premises and of the covenants herein contained, the Parties mutually agree as follows:
| 1. | Amendments. |
(a) Section 3.8.2.2 of the Agreement is amended and restated in its entirety as follows:
3.8.2.2 Hemispherx reserves the right to cancel or postpone any purchase order, provided that all postponements and cancellations are in accordance with each of the following terms:
| 3.8.2.2.1 | Should Hemispherx cancel or postpone all or part of any purchase order * or fewer calendar days prior to the scheduled fill date, Hemispherx shall pay Hollister-Stier a * fee equivalent to * of the purchase price for the entire purchase order. |
| 3.8.2.2.2 | Should Hemispherx cancel or postpone all or part of any purchase order less than * calendar days, but more than * calendar days prior to the scheduled fill date, Hemispherx shall pay Hollister-Stier a * fee equal to * of the purchase price for the entire purchase order. |
| 3.8.2.2.3 | Should Hemispherx cancel or postpone all or part of any purchase order less than * calendar days, but more than * calendar days prior to the scheduled fill date, Hemispherx shall pay Hollister-Stier a * fee equal to * of the purchase price for the entire purchase order. |
| 3.8.2.2.4 | Should Hemispherx cancel or postpone a purchase order * or more days before the scheduled fill date, Hollister-Stier will * . |
* Portions of this exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the Commission.
Confidential
C:
| C: 1 |
| 3.8.2.2.5 | The fees imposed under this Section 3.8.2.2 are * that will be imposed upon a rescheduled purchase order. |
(b) The following is appended to Section 3.8.3.: “The prices as of March 11, 2011, which are subject to increase on the next anniversary of the Effective Date are set forth on Exhibit B.”
(c) The Exhibit to this Amendment is appended to the Agreement, as Exhibit B.
(d) Section 8.1 is amended by replacing such Section with: “This Agreement shall remain in full force and effect for 3 years from the effective date of this Amendment, unless terminated earlier in accordance with the provisions hereof.
| 2. | Miscellaneous. |
2.1 Continuing Effect. This Amendment shall be effective for all purposes as of the Amendment Date. Except as otherwise expressly modified by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms.
2.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
2.3 Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Washington, irrespective of any conflicts of law rule which may direct or refer such determination of applicable law to any other state, and if this Amendment were performed wholly within the State of Washington.
* Portions of this exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the Commission.
Confidential
C:
| 2 |
In Witness Whereof, the Parties have executed this Amendment effective as of the Amendment Date.
| Hemispherx Biopharma, Inc. | ||
| By: | /s/ William A. Carter | |
| Name: | William A. Carter, M.D. | |
| Title: | CEO | |
| Date: | 9/9/11 | |
| Jubilant HollisterStier LLC | ||
| By: | /s/ Marcelo Morales | |
| Name: | Marcelo Morales | |
| Title: | CEO | |
| Date: | Sept 2, 2011 | |
* Portions of this exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the Commission.
Confidential
C:
| 3 |
EXHIBIT TO AMENDMENT FORMING EXHIBIT B TO SUPPLY AGREEMENT
PRICING AS OF MARCH 11, 2011
| December 8, 2010 |  |
Mr. Wayne Springate
Hemispherx Biopharma, Inc.
783 Jersey Ave.
RE: Document 576-2-25-0, 2011 Price Increase - Ampligen
Dear Mr. Springate:
Per Supply Agreement dated December 8, 2005, Section 3.8.3, Hollister-Stier is notifying you of a * increase in pricing for fill/finish services provided to Hemispherx Biopharma. Changes in pricing are based upon the annual percentage change in the Producer Price Index Industry:
Pharmaceutical Preparations. Pricing for product lots manufactured December 8, 2010 through December 7, 2011 will be as follows:
| AMPLIGEN | ||||
| CURRENT PRICING | PROPOSED PRICING | |||
| Media Fill Batch: | $ * | Media Fill Batch: | $ * | |
| Development Batch: | $ * | Development Batch: | $ * | |
| Registration/Commercial Batches: | $ * | Registration/Commercial Batches: | $ * | |
As always, we appreciate your business and
remain dedicated to the high standards of quality you
rely upon. If you have any questions, please feel free to contact me directly at 509-482-3541.
Best regards,
Director, Business Development
DMF/lec
* Portions of this exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the Commission.
Confidential
C:
| 4 |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/14/12 | |||
| For Period end: | 12/31/11 | |||
| 12/7/11 | ||||
| 3/11/11 | ||||
| 12/8/10 | 8-K | |||
| 2/26/10 | ||||
| 9/5/06 | ||||
| 2/28/06 | 4 | |||
| 12/8/05 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA 5/13/22 AIM ImmunoTech Inc. 10-Q 3/31/22 68:5.6M M2 Compliance LLC/FA 3/31/22 AIM ImmunoTech Inc. 10-K 12/31/21 90:9.3M M2 Compliance LLC/FA 3/31/21 AIM ImmunoTech Inc. 10-K 12/31/20 94:7.6M M2 Compliance LLC/FA |